Author

Qian Zhou 1

1 Abbvie,North Chicago,United States

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, John Liu, Ana P. Lacerda, Edward Loftus

High versus standard adalimumab induction dosing regimens in patients with moderately to severely active Crohn's disease: Results from the SERENE-CD induction study

Geert D‘Haens, William Sandborn, Edward Loftus, Steve Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Jean-Frédéric Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Qian Zhou, Bidan Huang, Nisha V. Kwatra, Nael M. Mostafa, Thao Doan, Joel Petersson, Alex Song, Anne M. Robinso

Long-term efficacy and safety of upadacitinib treatment in patients with Crohn´s disease: One-year results of the ongoing phase 2 CELEST open-label extension study

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, David Pugatch, John Liu, Ana P. Lacerda, Edward Loftus

OPERATING PROPERTIES OF DIFFERENT PATIENT REPORTED OUTCOME ENDPOINTS COMBINED WITH ENDOSCOPIC EVALUATION: DATA FROM EXTEND

Brian G. Feagan, William Sandborn, Paul Rutgeerts, Barrett G. Levesque, Reena Khanna, Anne M. Robinson, Bidan Huang, Qian Zhou, Holly A. read, Kori Wallace, Ana Paula Machado De Lacerda, Roopal B Thakkar

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

Joanne Rizzo, Jean-Frédéric Colombel, Stefan Schreiber, Geert R. D'Haens, Jenny Griffith, Javier Zambrano, Qian Zhou, Remo Panaccione, Marla C. Dubinsky, Jasmina Kalabic, Florian Rieder, Kristina Kligys

SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM CELEST

William J Sanborn, Brian G. Feagan, Julian Panés, Geert R. D'Haens, Jean-Frederic Colombel, Qian Zhou, Bidan Huang, J. V. Enejosa, Aileen L Pangan, Ana P. Lacerda

SUPERIOR ENDOSCOPIC AND DEEP REMISSION OUTCOMES IN ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE MANAGED WITH TREAT TO TARGET APPROACH VERSUS CLINICAL SYMPTOMS: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukas, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Z

Item 1 - 8 / 8
1